Literature DB >> 1888636

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

K Brøsen, E Skjelbo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1888636      PMCID： PMC1368510          DOI： 10.1111/j.1365-2125.1991.tb05630.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

1.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Elevated antidepressant plasma levels after addition of fluoxetine.

Authors:  A B Aranow; J I Hudson; H G Pope; T A Grady; T A Laage; I R Bell; J O Cole
Journal:  Am J Psychiatry       Date:  1989-07       Impact factor: 18.112

3.  Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression.

Authors:  I R Bell; J O Cole
Journal:  J Clin Psychopharmacol       Date:  1988-12       Impact factor: 3.153

4.  Interaction of fluoxetine with tricyclic antidepressants.

Authors:  D A Vaughan
Journal:  Am J Psychiatry       Date:  1988-11       Impact factor: 18.112

5.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

6.  Determination of imipramine and seven of its metabolites in human liver microsomes by a high-performance liquid chromatographic method.

Authors:  T B Zeugin; K Brosen; U A Meyer
Journal:  Anal Biochem       Date:  1990-08-15       Impact factor: 3.365

7.  Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Clin Pharmacol Ther       Date:  1986-11       Impact factor: 6.875

8.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Fluoxetine kinetics and protein binding in normal and impaired renal function.

Authors:  G R Aronoff; R F Bergstrom; S T Pottratz; R S Sloan; R L Wolen; L Lemberger
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

10.  Inhibitory effects of neuroleptics on debrisoquine oxidation in man.

Authors:  E K Syvälahti; R Lindberg; J Kallio; M De Vocht
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335
  10 in total
  25 in total

1.  Inhibitors of imipramine metabolism by human liver microsomes.

Authors:  E Skjelbo; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

Review 2.  The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors:  Norbert Thuerauf; Jens Lunkenheimer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

3.  Interaction between cyclosporin and fluoxetine.

Authors:  R C Horton; R S Bonser
Journal:  BMJ       Date:  1995-08-12

4.  Effect of fluoxetine on pharmacokinetics of ritonavir.

Authors:  D Ouellet; A Hsu; J Qian; J E Lamm; J H Cavanaugh; J M Leonard; G R Granneman
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

5.  Adverse drug reactions and debrisoquine/sparteine (P450IID6) polymorphism in patients with fibromyalgia.

Authors:  K J Skeith; M S Hussain; R T Coutts; C Ramos-Remus; J A Avina-Zubieta; A S Russell
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

6.  Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.

Authors:  Anna-Britta Lind; Margareta Reis; Finn Bengtsson; Michele Jonzier-Perey; Kerry Powell Golay; Johan Ahlner; Pierre Baumann; Marja-Liisa Dahl
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of fluoxetine.

Authors:  A C Altamura; A R Moro; M Percudani
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

Review 8.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

9.  Dextromethorphan O-demethylation polymorphism in Jordanians.

Authors:  Y M Irshaid; H F al-Hadidi; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

Authors:  H K Crewe; M S Lennard; G T Tucker; F R Woods; R E Haddock
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.